Targacept taps Stephen A. Hill to serve as president and CEO

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

Targacept taps Stephen A. Hill to serve as president and CEO

Targacept ($TRGT) tapped Stephen A. Hill to serve as president and CEO, effective Dec. 1. Hill will also join the company's board of directors. The doctor brings more than 20 years of industry experience to the role, having served previously as president and CEO of both Solvay Pharmaceuticals and ArQule ($ARQL). At Solvay, he led an organization of more than 1,200 employees until Abbott Laboratories ($ABT) acquired the company in 2010. And at ArQule, he led a successful transition from a fee-for-service discovery chemistry model to an enterprise with a proprietary clinical-stage pipeline. "I believe there is tremendous potential at Targacept to build upon a strong scientific and financial foundation and a promising clinical portfolio to deliver new treatment options to patients in need," Hill said in a statement. Release

Stephen A. Hill--Targacept
Hill will serve as president and CEO.

Robert G. Kramer--Emergent BioSolutions
Kramer will serve as chief financial officer.

Robert B. Darnell--New York Genome Center
Darnell will serve as president and scientific director.


> Emergent BioSolutions ($EBS) named Robert G. Kramer CFO. Kramer currently works as executive vice president of the corporate services division. He will continue in that position in addition to his new role. Release

> Echo Therapeutics ($ECTE) hired Daniel Sunday as vice president of manufacturing and global supply chain. Sunday joins Echo from Animas, a Johnson & Johnson ($JNJ) company. Release

> Aurobindo Pharma named Arvind Vasudeva as CEO (Formulations). Prior to joining the company, Vasudeva served as chief operating officer at Glenmark Pharmaceuticals. News

> Microbix Biosystems called upon Vaughn Embro-Pantalony to serve as president and CEO. Embro-Pantalony has served as a senior executive at Novopharm and Bayer Healthcare, among others. Release

> Kala Pharmaceuticals added Bernard Gilly to its board of directors. Gilly most recently served as founding chairman and CEO of Fovea Pharmaceuticals. Release

> Regulus Therapeutics ($RGLS) named Victor Knopov vice president of pharmaceutical development. Knopov signs on with the company from Nitto Denko Technology. Release

> ImmunoGen ($IMGN) announced Charles Morris will serve as executive vice president and chief development officer. Morris was the executive vice president and chief medical officer at Allos Therapeutics. Release

> Genzyme called upon Brendan Martin to work as its new general manager for the U.K. and Ireland. Martin joined the company in 2002. News

> Ampio Pharmaceuticals ($AMPE) tapped Josh Disbrow to work as COO, effective Dec. 15. Disbrow most recently served as vice president of commercial operations at Arbor Pharmaceuticals. Release

> Bruce Beutler joined Sound Pharmaceuticals as a scientific adviser. Beutler won the Nobel Prize in physiology or medicine for his discoveries involving the activation of innate immunity. Release

Medical Devices

> AngioDynamics ($ANGO) named Mark Frost CFO starting Feb. 1, when D. Joseph Gersuk will retire. Frost had been CFO at AMRI ($AMRI) until September. News


> Reckitt Benckiser appointed Suzanne LoGalbo as regulatory affairs director of Reckitt Benckiser North America. LoGalbo joins the company from Pfizer Consumer Health. More


> Pacific Biomarkers added Maribeth Raines to its team as vice president of laboratory services. Raines was most recently director of scientific affairs for Quest Diagnostics Clinical Trials. Release


> Onyx Scientific strengthened its U.S. presence by appointing Dan Brisard to oversee the organization's business development activities across the eastern half of the country. Brisard most recently spent 7 years with Ricerca Biosciences. Release

Biotech Research

> The New York Genome Center tapped Robert B. Darnell to serve as the organization's first president and scientific director. Darnell is a Rockefeller University physician-scientist and Howard Hughes Medical Institute investigator. Article

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.